AcrySof IQ Toric A-Code Post-Market Clinical Study
Launched by ALCON RESEARCH · Nov 17, 2017
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Patients will be examined pre-operatively to up to 3 years post-operatively. One eligible eye will be selected as a target eye for efficacy analysis. If both eyes are eligible, the eye in which the IOL is implanted first will be selected as the target eye.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of cataracts with planned cataract removal by phacoemulsification
- • Calculated lens power within the available range
- • Able to sign informed consent and complete all study visits
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Eye conditions as specified in the protocol
- • Uncontrolled glaucoma
- • Pregnancy, current or planned
- • Other protocol-defined exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hiroshima, Hiroshima Prefecture, Japan
Hakodate, Hokkaido, Japan
Miyakonojō, Miyazaki Prefecture, Japan
Saga, Saga Prefecture, Japan
Patients applied
Trial Officials
Expert Clinical Project Lead, CDMA Surgical
Study Director
Alcon Research, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials